Songqing Na is a prominent inventor based in San Marcos, California. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies. With a total of three patents to his name, Na's work has the potential to impact various therapeutic applications.

Latest Patents

One of Songqing Na's latest patents involves human interleukin-4 receptor alpha antibodies. This patent discloses antibodies that specifically bind to human IL-4Rα, along with compositions and methods for using these antibodies. Another notable patent is for anti-human CD19 antibodies, which details antibodies that bind to human CD19, as well as compositions and methods for their application.

Career Highlights

Songqing Na is currently employed at Eli Lilly and Company, a leading global pharmaceutical company. His work at Eli Lilly focuses on advancing therapeutic solutions through innovative antibody research. Na's expertise in this area has positioned him as a valuable asset to his team and the broader scientific community.

Collaborations

Some of Songqing Na's coworkers include Rohn Lee Millican, Jr. and Neungseon Seo. Their collaborative efforts contribute to the ongoing research and development of novel therapeutic antibodies.

Conclusion

In summary, Songqing Na is an influential inventor whose work in antibody development is paving the way for new therapeutic options. His contributions to the field are noteworthy and demonstrate the importance of innovation in biotechnology.

This text is generated by artificial intelligence and may not be accurate.